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Abstract
Loss of the survival motor neuron gene (SMN1) is responsible for spinal muscular atrophy (SMA), the most common
inherited cause of infant mortality. Even though the SMA phenotype is traditionally considered as related to spinal
motor neuron loss, it remains debated whether the specific targeting of motor neurons could represent the best
therapeutic option for the disease. We here investigated, using stereological quantification methods, the spinal cord
and cerebral motor cortex of ∆7 SMA mice during development, to verify extent and selectivity of motor neuron loss.
We found progressive post-natal loss of spinal motor neurons, already at pre-symptomatic stages, and a higher
vulnerability of motor neurons innervating proximal and axial muscles. Larger motor neurons decreased in the course
of disease, either for selective loss or specific developmental impairment. We also found a selective reduction of
layer V pyramidal neurons associated with layer V gliosis in the cerebral motor cortex. Our data indicate that in the
∆7 SMA model SMN loss is critical for the spinal cord, particularly for specific motor neuron pools. Neuronal loss,
however, is not selective for lower motor neurons. These data further suggest that SMA pathogenesis is likely more
complex than previously anticipated. The better knowledge of SMA models might be instrumental in shaping better
therapeutic options for affected patients.
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Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive
neuromuscular disease. It is the most common inherited cause
of infant mortality with an incidence of around 1 in 10000 live
births and a carrier frequency of 1:31 [1]. The major
anatomopathological hallmark of SMA consists in the
degeneration of spinal motor neurons associated with a
progressive atrophy of the limb and trunk muscles and, in the
most severe cases, death. Based on the age of onset and
disease severity, SMA has been classified into four main
clinical types (I-IV) caused by homozygous loss or mutation of
the Survival Motor Neuron 1 (SMN1) gene [2]. In humans,
there are two SMN genes, the telomeric SMN1 coding for an
ubiquitous protein (full-length SMN or FL-SMN), and its
centromeric homolog SMN2 mostly generating a protein
lacking exon 7 (Δ7-SMN), which is thought to be not functional
or rapidly degraded [3-5]. The SMN2 gene does, however,
produce a 10% of FL-SMN so that high copy number of SMN2
can dampen the clinical severity of SMA [6,7]. The 38 KDa FL-
SMN protein is expressed in both the cytoplasm and the
nucleus and plays a critical role in small nuclear
ribonucleoproteins (snRNPs) assembly and pre-mRNAs
maturation [8,9]. However, SMN also localizes in motor neuron
axons in vivo [10,11] and a specific axonal role of the protein
was proposed [12,13]. The role of SMN in axons received
further support by the identification of an axonal form of SMN
(a-SMN) [14], more selectively expressed in motor neuron
axons and involved in axonogenesis. However, the molecular
and cellular mechanisms by which SMN1 gene mutations
eventually lead to a selective failure of the neuromuscular unit
remain unclear.
Different mouse models of SMA were generated to
understand disease pathogenesis [15-18]. Homozygous Smn
gene deletion resulted in massive cell death before
implantation [19], whereas engineering several copies of the
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human SMN2 transgene on the Smn-null background
prevented embryo-lethality and introducing additional mutated
[20,21] or exon 7-deleted [17] human SMN1 cDNAs variously
extended mice survival. Heterozygous Smn+/- mice [22] or
Smn2B/- mice harboring an allele mutated in the splicing
enhancer region of exon 7 [15,23] displayed mild/ intermediate
phenotypes.
The most frequently used model is the Δ7 SMA mouse
(SMN2+/+; SMN Δ7+/+; Smn -/-) [17], with a lifespan of about 2
weeks and early impairment of motor behavior correlated with
motor neuron loss. These mice have been also widely used to
test different therapeutic approaches, including viral-mediated
gene delivery and anti-sense oligonucleotides up-regulating
FL-SMN transcript levels [24-26]. Although different aspects of
the Δ7 model have been analyzed in a number of studies
[17,27], discrepancies still exist on the number and subgroups
of spinal motor neurons affected during disease progression.
Furthermore, analysis of brain morphology and evaluation of a
possible vulnerability of the upper motor system have not been
carried out in Δ7 mice.
In the present study, we have characterized the spinal cord
and brain of Δ7 mice during development. We demonstrated
through stereological analysis in the cervical spinal cord that
motor neuron loss occurred progressively from early post-natal
stages but not at pre-natal stages. In addition, motor neuron
loss was more selective for larger motor neurons, particularly
those innervating proximal and axial muscles. Finally,
quantification of cell density in the motor cortex revealed a
specific loss of layer V pyramidal neurons, indicating that




All the procedures involving animals were performed in
accordance with national (DL n. 116, G.U., Supp. 40, February
18, 1992) and European Community Council guidelines (EEC
Council Directive 86/60, OJ L 358, 1, December 12, 1987,
Guide for the Care and Use of Laboratory Animals, U.S.
National Research Council, 1996). The experimental protocol
was approved by the Ethics Committee of the “C. Besta”
Neurological Institute and by the Italian Ministry of Health
(protocol number: BT1/2012). Particular care was taken to
minimize the number of animals, their discomfort and pain.
Experimental animals
The original breeding pairs of Δ7 mice were purchased from
Jackson Laboratory (stock number 005025; Jackson Lab,
Maine, USA). The colony was maintained by interbreeding
carrier mice, and the offspring were genotyped by PCR assays
on tail DNA according to the protocols provided by Jackson
Laboratory. Mice had free access to food and water. Data were
obtained from tissues harvested from Smn-/- (SMA) and Smn+/+
(WT) mice sacrificed at embryonic stage 19 (E19), checked by
vaginal plug examination, postnatal day 4 (P4, pre-
symptomatic stage), P9 (fully-symptomatic) and P13 (terminal
stage), considering P0 as the day of birth.
Tissue preparation
Pups were deeply anaesthetized by intraperitoneal injections
of 4% chloral hydrate (10 ml/Kg) and trans-cardially perfused
with 4% paraformaldehyde in phosphate buffer (0.1 M PB, pH
7.2). Brains were removed, weighed and immersed in fixative
for 2 h at 4°C. Samples were transferred overnight into 30%
sucrose in 0.1 M PB at 4°C for cryoprotection, embedded in
medium (Killik; Bio-Optica, Milan, Italy) and cut with a cryostat
(Microm HM 550; Thermo Fisher Scientific Inc, Waltham, MA,
USA). P4 and P9 brains were cut in serial 20 μm-thick coronal
sections and mounted onto gelatin-coated slides to be
processed for immunostaining. E19, P4 and P13 cervical spinal
cords were dissected out, embedded in warm 6% Agar (Sigma
Aldrich, St. Louis, MO, USA), and cut on a vibratome (Leica
VT1000S; Heidelberg, Germany) in serial coronal 25 μm-thick
(for embryos) or 30 μm-thick (for pups) sections.
Histology, immunohistochemistry and confocal
imaging
For Nissl staining, brain and spinal cord sections were
mounted on 2% gelatin-coated slides and air-dried overnight.
Sections were then hydrated in distilled water, immersed in
0.1% Cresyl violet acetate or 0.1% thionine (Sigma Aldrich)
and cover-slipped with Eukitt (Bioptica). For
immunohistochemistry (IHC), unspecific binding sites were
blocked with 5% bovine serum albumin (BSA), 1% Triton X-100
for 2 h at room temperature (RT), immersed in 3% hydrogen
peroxide (H2O2) to remove the endogenous peroxidase activity,
rinsed in phosphate buffer saline (PBS) and incubated with
goat polyclonal anti-Choline Acetyl Transferase (ChAT)
antibody (Millipore, Billerica, MA, USA: diluted 1:150) overnight
at RT in a humidified chamber. After rinsing in PBS, sections
were incubated with biotinylated donkey anti-goat IgG (Santa
Cruz Biotechnology, Santa Cruz, CA, USA: diluted 1:200) for 2
h, rinsed in PBS and then incubated with ExtrAvidin-peroxidase
(Sigma Aldrich: diluted 1:4000) for 1 h. All antibodies were
diluted in 0.01M PBS, 3% BSA, 0.5% Triton X-100. Peroxidase
staining was obtained by incubating the sections in 0.075%
3,3’-diaminobenzidine tetrahydrochloride (DAB; Sigma Aldrich)
and 0.002% H2O2 in 50 mM Tris-HCl pH 7.5. Section were air
dried, dehydrated and coverslipped with DPX (BDH Prolabo,
Dublin, Ireland). Adjacent sections were counterstained with
0.1% thionine or Cresyl violet acetate. For confocal imaging,
free-floating sections were pre-treated with 4% sucrose in PBS
and 100% cold methanol for 30 min, and aspecific binding sites
were blocked with 10% normal goat serum (NGS) or normal
donkey serum (NDS) in PBS with 0.2% Triton X-100 for 1 h at
RT. Sections were then incubated overnight at 4°C with
monoclonal mouse anti-Glial Fibrillary Acid Protein (GFAP:
diluted 1:500) or monoclonal mouse anti-neurofilament-SMI32
(Covance, Emeryville, CA, USA: diluted 1:1000) antibodies. All
primary antibodies were diluted in 1% NGS and 0.3% Triton
X-100 in PBS. After rinsing in PBS, sections were incubated in
biotinylated anti-mouse IgG (Jackson ImmunoResearch
Laboratories; West Grove, PA, USA: diluted 1:200 in 1% NGS
in PBS) for 1 h, followed by Cy2-conjugated Streptavidin
(Jackson ImmunoResearch Laboratories: diluted 1:200 in 1%
NGS in PBS). Finally, sections were incubated with the pan-
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neuronal fluorescent marker NeuroTraceTM (Molecular Probes,
OR, USA: diluted 1:200), mounted on slides and examined on
a Radiance 2100 (Bio-Rad, Hercules, CA, USA) or Leica TCS
SP5 confocal laser-scanning microscopes (Leica).
Spinal cord stereological counts
Stereological counts were performed at C3-C5 in post-natal
mice and whole cervical levels in embryos, on both cresyl violet
(for each genotype: E19, n=3; P4, n=3; and P13, n=5) and
ChAT stained (P4, n=3; P13, n=4) sections. In Nissl-stained
sections, the nucleoli of spinal motor neurons in ventral horns
were counted at 40X magnification. Only neurons with an area
≥ 80 μm2 and located in a position congruent with that of motor
neuron groups were counted [28]. All ChAT+ profiles located in
the ventral horns of immunoreacted sections clearly displaying
a nucleolus on the plane of the section were counted. Total
estimated motor neuron numbers were obtained with the
Optical Fractionator [29], using a computer-assisted
microscope and the StereoInvestigator software
(MicroBrightField, Williston, VT, USA). Cells were counted on
the computer screen using an Optronics MicroFire digital
camera mounted on a Nikon Eclipse E600 microscope. Ventral
gray matter volume data from the reconstructed segments
were also obtained with the associated data analysis software
NeuroExplorer (MicroBrightField). One 30 μm-thick ChAT-
reacted section every five and one Nissl-stained section every
fifteen were reconstructed at P4; one ChAT-positive and Nissl-
stained section every eighteen were reconstructed at P13; one
25 μm-thick Nissl-stained section every eighteen was
reconstructed at E19. The guard zones were 3 μm, the
counting frame size was 75 × 75 μm and the sampling grid size
100 × 100 μm. The soma size of ChAT+ motor neurons was
also analyzed in P4 and P13 mice at C3-C5 levels.
Spinal motor neuron pool analysis. Four cervical motor
neuron pools (phrenic nucleus at C4, deltoid and biceps at C5-
C6, forearm muscles at C8-T1 levels, medial Ax9 at C1-C8)
were identified in serial Nissl-stained and ChAT-reacted
sections [30] of P4 (n=3) and P13 (n=4) mice. Sections (at
least 3 sections for each motor neuron pool considered) were
photographed with AxioCam MRc5 camera connected to
Axioplan 2 Imaging microscope (Zeiss, Oberkochen, Germany)
and soma cross-sectional areas measured at 40X
magnification using Axiovision 4.8 software (Zeiss). Only cell
bodies clearly showing a nucleolus on the plane of the section
were considered. Mean motor neuron areas were calculated for
each pool, and size distribution histograms (expressed in
percentage) were constructed by grouping cross-sectional
areas in 100 µm2 bins.
Motor cortex analysis
Cortical sections at P4 (n=3 for each genotype) and P9 (WT,
n=4; SMA, n=3) stained with Cresyl violet were analyzed using
the Neurolucida software program (Microbrightfield Inc.). Motor
cortex (relative to one hemisphere) was identified and cell
counts were performed in layers II-III and V. One 20 μm-thick
section every five was reconstructed in a cerebral segment
corresponding to plates 29, 36 and 39 of the Franklin and
Paxinos atlas [31], and counts were performed at 40X
magnification. The density of neurons was obtained using
Neurolucida Explorer for computer-aided microscopy
(Microbrightfield Inc.). The total number of counted cells was
divided by the measured motor cortex surface area (expressed
in μm2), and then multiplied by the section thickness (20 μm) in
order to obtain a density volume value. Soma size of layer II-III
and V pyramidal neurons was also measured in the motor
cortex by random sampling (WT mice n=3; SMA mice n=3).
Neuronal profiles of at least 100 cells (with the nucleolus on the
plane of the section and avoiding the glial cells, identified by
their smaller size) were outlined with the Neurolucida software
and data analyzed with Neurolucida Explorer.
Astrogliosis quantification
GFAP immunoreactivity was also analyzed to evaluate
astroglial activation. The density of GFAP+ immunofluorescent
profiles was quantified both in brain and spinal cord by 2
separate observers. Four areas were selected: layers II-III and
V in motor cortex (1.42 mm and 0.26 mm from bregma), spinal
ventral and dorsal horns at C5, for each animal (WT mice n=3;
SMA mice n=4, two sections for each animal) at P13. These
areas were photographed at 40X magnification using AxioCam
MRc5 connected to the Axioplan2 Imaging microscope and
fluorescence intensity quantified, after subtraction of
background, using the ImageJ-ProPlus software. The intensity
of fluorescence was expressed in Arbitrary Units (AU) as mean
± SEM.
Western Blot Analysis
Spinal cords were quickly removed from P4 and P13 WT
mice after decapitation, then immediately frozen on dry ice and
stored at -80° C until use. Samples were homogenized in buffer
containing 20 mM Hepes (pH 7.4), 1 mM DTT, 0.1 mM PMSF
and Complete (Roche, Indianapolis, IN, USA). Protein extracts
were separated by 12 % SDS-PAGE, electroblotted onto
nitrocellulose membranes, probed with goat polyclonal anti-
ChAT antibody (Millipore: diluted 1:150 in 3% non-fat milk) and
analyzed with chemiluminescence (ECL; Amersham Int., Little
Chalfond, UK). A monoclonal antibody against actin was used
as loading control (Millipore: diluted 1:4000 in 3% non-fat milk).
Statistics
The values from each animal were averaged and each
genotype group (WT and SMA) compared to achieve the p-
value by unpaired Student’s t-test, two tails. Data for Student’s
t-test significance were performed in Microsoft Excel. To test
the differences in area size-interval frequencies between the
two experimental groups (WT and SMA) we applied the chi-
square test, using a free web utility (http://www.quantpsy.org/
chisq/chisq.htm). Data were expressed as mean ± SEM
(standard error of the mean) and differences were considered
significant when p ≤ 0.05.
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Results
Time course of spinal motor neuron loss in SMA
To verify the onset and progression of spinal motor neuron
loss, we first compared stereological counts on ChAT
immunoreacted sections at cervical C3-C5 levels in SMA (-/-)
vs WT (+/+) mice, at pre- (P4) and late- (P13) symptomatic
stages. Even at low magnification (Figure 1A), the ventral horn
area of ChAT+ motor neuron cell bodies and neuropil was
smaller in SMA mice vs WT at both P4 and P13. The smaller
size was more evident at C5, where motor neurons innervating
proximal forelimb muscles were located. Stereological analysis
revealed that motor neuron number was decreased at P4 (SMA
2117 ± 84 cells; WT 3024 ± 366 cells, p > 0.05, t-test; Figure
1B left) and significantly reduced at P13 (SMA 2863 ± 242
cells; WT 4705 ± 630 cells, *p < 0.05; Figure 1B right). The
apparently contradictory increase in ChAT+ motor neuron
number at P13 vs P4 in both WT and SMA mice was explained
as due to age-dependent maturation in ChAT expression by
western blot experiments, demonstrating increased ChAT
expression between P4 and P13 in the ventral spinal cord of
WT mice (Figure 1C). Progression of spinal cord atrophy was
also confirmed by volume analysis of the ventral C3-C5
segments (P4: 0.6 ± 0.02 mm3 in SMA vs 0.7 ± 0.04 mm3 in
WT, p>0.05, t-test; P13: 0.8 ± 0.08 mm3 in SMA vs 1.3 ± 0.06
mm3 in WT, **p<0.01).
The reduction in motor neuron number at P4 could be related
to early motor neuron loss but also due to impairment of motor
neuron development during spinal cord ontogenesis. We
therefore verified cervical motor neuron numbers in pre-natal
(E19) and post-natal (P4 and P13) SMA mice and WT controls
in Nissl-stained sections (Figure 2A), to avoid possible
confounding bias from the age-dependent expression of ChAT.
Stereological counts carried out in the whole cervical tract at
E19 did not reveal differences in motor neuron number in SMA
vs WT mice (Figure 2B). In keeping with data on ChAT+ motor
neurons, progressive reduction of Nissl-stained motor neurons
occurred during post-natal stages, becoming significant at P13,
Figure 1.  Stereological analysis of ChAT+ motor neurons.  (A) Low-power images of ChAT immunoreacted spinal cord sections
at ventral C3-C5 cervical levels from WT (upper) and SMA (lower) mice at pre- (P4, left) and late-symptomatic (P13, right) disease
stages. Note that the C5 area of ChAT+ immunoreactivity was smaller in SMA than in WT mice at both P4 and P13. (B)
Stereological analysis revealed that total motor neuron number was reduced at P4 (left) and significantly decreased at P13 (right) in
SMA compared to WT mice (*p<0.05, t-test). (C) Western-blot analysis revealed increased ChAT expression between P4 and P13 in
WT mice. Values are expressed as mean ± SEM. Scale bar: 100 µm.
doi: 10.1371/journal.pone.0082654.g001
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i.e., when motor neuron function was clearly impaired (P4:
6103 ± 264 motor neurons in SMA mice, 7703 ± 1774 in WT,
p>0.05, t-test; P13: 5180 ± 657 motor neurons in SMA, 7798 ±
716 in WT, *p< 0.05; Figure 2B).
Loss of large motor neurons in SMA
The reduced ChAT+ neuropil area at P4, i.e., at a stage when
motor neuron number was not significantly reduced, prodded
us to measure the size of C3-C5 ChAT+ motor neurons. Motor
neurons were significantly smaller in SMA vs WT mice at P4
and P13, indicating the possibility that motor neurons
underwent atrophy before dying (P4: 324 ± 4.3 µm2 in SMA and
394.7 ± 3.8 µm2 in WT, ***p < 0.001, t-test; P13: 316.4 ± 15.3
µm2 in SMA and 438 ± 11.3 µm2 in WT, ***p < 0.001; Figure 3A).
The distribution of motor neuron soma size was significantly
shifted to the lower area size at P4 and more clearly at P13
(***p<0.001, chi-square test, at both ages; Figure 3B and C),
and the percentage of motor neurons with cross-sectional area
greater than 500 µm2 was reduced both at P4 (9.7 ± 0.8% vs
20.54 ± 1.2%, **p<0.01, t-test) and P13 (8.7 ± 2% vs 37 ± 3%,
***p<0.001, t-test) in SMA vs WT mice. These data might
indicate in ∆7 SMA mice either a more selective loss of larger
motor neurons or a developmental failure leading to smaller
motor neurons.
Selective vulnerability of motor neurons innervating
proximal and axial muscles
Since different muscle groups are differently affected in
SMA, we compared in WT vs SMA mice four specific motor
neuron pools of the cervical region at P4 and P13: (i) phrenic
motor neurons at C4, innervating the diaphragm, (ii) lateral
motor neurons at C5-C6, innervating forelimb proximal
muscles, (iii) lateral motor neurons at C8, innervating forelimb
distal muscles, and (iv) medial Ax9 motor neurons at C1-C8,
innervating axial muscles (see Figures 4A and 5A for
representative motor neuron pools at P13). We found that
mean somatic area in SMA vs WT mice was reduced in motor
neurons innervating proximal forelimb and axial muscles only
(Figures 4B and 5B, D). The reduction was already significant
at P4 (**p<0.01, t-test; Figures 4B left and 5B) and even more
evident at P13 (***p < 0.001; Figures 4B right and 5D). By
contrast, mean area was unmodified in phrenic motor neurons
and slightly but not significantly reduced in motor neurons
innervating distal forearm muscles (Figure 4B). The distribution
of soma size in motor neurons innervating proximal and axial
muscles revealed a statistically significant shift to the lower
area size at P4 and more clearly at P13 (***p<0.001 at both
ages, chi-square test between SMA and WT curves; Figures
4C and 5C, E), further indicating either more selective
vulnerability of large size motor neurons or developmental
impairment in these motor neuron pools. By contrast, soma
size distribution analysis of the two other motor neuron pools
did not reveal evident changes (Figure S1).
Loss of layer V pyramidal neuron of motor cortex
We next investigated whether Smn deletion affected also the
upper motor neuron compartment by analyzing brain
morphology at pre- (P4) and symptomatic (P9 and P13) stages,
with particular attention to layers II-III and V of the motor
cortex. Whole brain comparison between SMA and WT mice
revealed a clear reduction in size and weight at P13 (SMA
307.4 ± 13.4 mg vs WT 423 ± 25 mg, ***p < 0.001, t-test; Figure
6A right, 6B) but not at P4 (SMA 190.5 ± 8.3 mg vs WT 182.6 ±
4.6 mg, p > 0.05; Figure 6A left, 6B). Stereological counts
performed on Nissl-stained coronal brain sections (Figure 6C)
revealed that cell density of pyramidal neurons in layer V was
slightly reduced in SMA vs WT mice at P4 (SMA 2278320 ±
179975 cells/mm3; WT 2896685 ± 435636 cells/mm3, p >0.05,
t-test) and significantly decreased at P9 (SMA 1056858 ±
176559 cells/mm3; WT 2219833 ± 218528 cells/mm3, **p <
0.01; Figure 6D). By contrast, cell density in layers II-III did not
differ between SMA and WT mice at either stages (data not
shown), suggesting that layer V neurons, i.e., long-projecting
corticofugal neurons, were more selectively susceptible in SMA
mice. At fully-symptomatic stages (P9), the mean area of
pyramidal neurons was slightly but not significantly reduced in
both layers II-III and V (Figure S2) and the soma size
distribution analysis of both layers II-III and V neurons did not
reveal evident changes (Figure S2).
Glial activation in SMA mice
We finally evaluated cerebral and spinal glial activation in
sections reacted for GFAP immunofluorescence (IF) in SMA vs
WT mice at P4 and P13 (Figure 7). GFAP+ IF signal did not
differ between SMA and WT mice at P4 in either C5 spinal cord
and cerebral motor cortex (Figure 7A and C, upper). By
contrast, reactive gliosis was significantly increased in SMA vs
WT mice at P13 in both spinal cord and cerebral cortex (Figure
7A and C, lower, 7B and D, ***p < 0.001, t-test). Interestingly,
reactive gliosis was increased in both ventral and dorsal horns
of the spinal cord (Figure 7B) but selectively in layer V (and not
layers II-III) of the motor cortex (Figure 7D), supporting the
selective neuronal loss in layer V described above.
Discussion
We have here investigated motor neuron loss in the spinal
cord and cerebral motor cortex of ∆7 mice [17], the most widely
used SMA model, using stereological quantification methods.
We found progressive post-natal loss of spinal motor neurons,
already at pre-symptomatic stages, and a higher vulnerability of
larger motor neurons and those innervating proximal muscles.
We also demonstrated a selective reduction of layer V
pyramidal neurons in the cerebral motor cortex. Our data
indicate therefore that, at least in this model, i) SMN loss is
particularly critical for specific motor neuron pools; and ii)
neuronal loss is not strictly selective for spinal motor neurons.
Methodological considerations
Our stereological analysis was performed on spinal cords
processed for IHC with the specific motor neuron marker
ChAT, and Nissl staining. ChAT labels motor neurons
selectively, but is age-dependent, since ChAT expression
matures through development. In addition, ChAT does not
identify early pathologic events in SMA, since the occurrence of
chromatolitic, ChAT+ motor neurons can be observed only after
Motoneuronal Vulnerability in Delta7 SMA Mice
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Figure 2.  Stereological analysis of Nissl-stained motor neurons.  (A) Representative Nissl-stained coronal sections of ventral
C5 spinal cord from WT (left) and SMA (right) mice at prenatal (E19, upper), pre- (P4, middle) and late-symptomatic (P13, lower)
disease stages. (B) No difference in the total cervical motor neuron number was evident at prenatal stages (E19, left), whereas a
progressive reduction was evident post-natally (P4, middle), reaching statistical significance at late-symptomatic stages (P13, right:
*p<0.05, t-test). Values are expressed as mean ± SEM. Scale bar: 100 µm.
doi: 10.1371/journal.pone.0082654.g002
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Figure 3.  Large motor neurons are selectively affected in SMA.  (A) Quantitative analysis at C3-C5 spinal levels revealed a
significant reduction of mean motor neuron area in SMA vs WT mice at P4 (left) and P13 (right, ***p<0.001, t-test). (B, C) The
analysis of the distribution of motor neuron areas (bins=100 µm2) revealed a significant shift to lower size in SMA vs WT mice at
both P4 and P13 (***p<0.001, chi-square test between WT and SMA curves). Also note the reduction of motor neurons larger than
500 µm2 in SMA mice. Values are expressed as mean ± SEM.
doi: 10.1371/journal.pone.0082654.g003
Motoneuronal Vulnerability in Delta7 SMA Mice
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birth in SMAI patients [32]. Nissl staining labels all cells from
the earliest stages of development, allowing identifying motor
neurons by their size and position, but it might exclude smaller
motor neurons or, vice versa, include different neurons such as
large spinocerebellar cells located in the ventral horns.
Previous data, based on non-stereological analysis, provided
different quantification of motor neuron loss in ∆7 mice, ranging
from no loss to 25% loss in lumbar motor neurons at terminal
stages [27,33]. The use of both methods, allowing the analysis
of the time-course of motor neuron loss through development
Figure 4.  Selective loss of proximal motor neurons.  (A) Representative ChAT reacted coronal sections of the cervical spinal
cord illustrating 3 different motor neuron (MN) pools (hatched lines) in WT at P13: phrenic MNs at C3 level (a1), lateral MNs at C5-
C6 innervating forelimb proximal muscles (a2), and lateral MNs at C8 innervating forelimb distal muscles (a3).
(B) Quantitative analysis of mean areas of the 3 MN pools in SMA vs WT mice revealed a significant soma size reduction only in the
MN pool innervating proximal forelimb muscles (left, P4: 386.3 ± 22.5 µm2 in SMA vs 526.5 ±15 µm2 in WT, **p < 0.01, t-test; right,
P13: 378 ± 13 µm2 in SMA vs 599.7 ± 20.7 µm2 in WT, ***p < 0.001). Mean area were unchanged in phrenic MNs (left) and not
significantly reduced in MNs innervating distal muscles (right). (C) The analysis of soma size distribution of MNs innervating
proximal muscles revealed a significant shift to lower size in SMA vs WT mice at P4 (left) and even more at P13 (right) (***p<0.001,
chi-square test between WT and SMA curves). Values are expressed as mean ± SEM. Scale bar: 100 µm.
doi: 10.1371/journal.pone.0082654.g004
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Figure 5.  Selective loss of axial motor neurons.  (A) Representative ChAT reacted coronal sections of the cervical spinal cord
illustrating Ax9 medial motor neurons (hatched lines) innervating axial muscles in WT (left) and SMA (right) at P13. Note the smaller
neuronal size in SMA vs WT mice. (B, D) The average cross-sectional area was significantly reduced in SMA mice at both P4 (B)
and P13 (D) stages (P4: 280 ± 8 µm2 in SMA vs 371 ±10.5 µm2 in WT, **p < 0.01, t-test; P13: 258 ± 7 µm2 in SMA vs 392 ± 14 µm2
in WT, ***p < 0.001). (C, E) The distribution of MN cross-sectional areas at both P4 (C) and P13 (E) showed a significant shift to
lower size in SMA vs WT mice (***p<0.001, chi-square test between WT and SMA curves). Values are expressed as mean ± SEM.
Scale bar: 100 µm.
doi: 10.1371/journal.pone.0082654.g005
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(by Nissl staining) and the precise differences in motor neuron
number between WT and SMA mice (by ChAT staining),
indicated clearly that progressive death of motor neurons is a
relevant event taking place in the spinal cord of ∆7 mice.
Motor neuron loss in the spinal cord
Indeed, the presence of comparable cervical motor neurons
counts at E19 in both ∆7 SMA mice and WT indicated that
motor neuron development in Δ7 mice was not grossly
impaired by Smn deficiency. By contrast, the progressive
reduction of motor neuron counts in SMA vs WT mice (30%
motor neuron loss at P4 and further 10% occurring between P4
and P13) demonstrated a neurodegenerative process taking
place in Smn-depleted motor neurons. These data also
suggest that motor neuron death is more severe in early post-
natal stages, followed by a period of relative stability
characterized by minor motor neuron loss. The time course of
motor neuron loss is in agreement with previous data reporting
no further denervation of vulnerable neuromuscular junctions
(NMJs) in ∆7 mice after P7 [34].
The precise evaluation of number and post-natal fate of
motor neurons simply portrays the end-point but it does not
describe the whole neurodegenerative process, since many
subtle changes might affect the proper function of the motor
unit before motor neuron loss. Recent studies in ∆7 SMA mice
demonstrated altered Ca2+ homeostasis and morpho-functional
abnormalities of the NMJs preceding motor neuron loss, and
neurofilament accumulation in axons and terminals without
wallerian degeneration, therefore suggesting that failure of
NMJ maintenance and/or the proper crosstalk between axon
terminals and muscle fibers could be the first step in the
pathogenesis of SMA [27,35-37]. However, many other factors
should be considered. Motor neurons in ∆7 mice are
Figure 6.  Loss of layer V pyramidal neurons of motor cortex.  (A) Photographs of P4 and P13 mouse brains showing a clear
reduction of brain size in SMA vs WT mice at P13 (right). No difference in size were observed at P4 (left). (B) Quantitative analysis
of brain weight in SMA vs WT littermates at P4 and P13. A weight reduction of about 30% was observed at late-symptomatic (P13:
***p<0.001, t-test) but not at pre-symptomatic (P4) stages. (C) Nissl-stained brain sections illustrating reduced numbers of larger
pyramidal neurons (red asterisks in the inset) in layer V of SMA mice vs WT controls. (D) Stereological counts of Nissl-stained brain
sections revealing a significant 52% decrease (**p<0.01, t-test) of pyramidal neuron density in layer V of P9 SMA vs WT mice. The
density of pyramidal neurons was already reduced at P4, without reaching statistical significance (p>0.05). Values are expressed as
mean ± SEM. Scale bars: 5 mm in A; 50 µm in C.
doi: 10.1371/journal.pone.0082654.g006
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hyperexcitable, receive reduced central synapses and
VGLUT1+ proprioceptive sensory inputs before motor neuron
loss [38,39], and axonal swellings and muscular denervation
were reported in embryonic severe and ∆7 SMA mice [34,40],
clearly indicating more subtle motor unit damage well before
the establishment of a clear motor phenotype. Altered
neuromuscular transmission does not fully explain motor
paralysis in SMA mice, and, even though axial muscles are
more vulnerable and motor neuron death is more prominent in
the medial than in the lateral motor column, neither muscle
location nor fiber type (i.e., fast vs slow twitch) or motor unit
phenotype (i.e., fast- vs delayed-synapsing) [41] could be
considered as selective determinants of motor failure in SMA
mice [34,36-38]. Careful muscle analysis in ∆7 SMA mice
suggested the pathogenic relevance of neuromuscular
development defects [42]. Apoptotic mechanisms can also play
a major role in motor neuron death in SMA, as suggested by
data from human post-mortem specimens of SMA type I
patients [43,44] and animal models [45,46]. Finally, it should be
remembered that failure in motor neuron migration was
Figure 7.  Glial activation in Δ7 SMA mice.  Coronal sections from cervical spinal cord (A) and brain (C) of WT (left) and SMA
mice (right) stained with Neurotrace (red) and GFAP-immunoreacted (green). Note glial activation in the spinal cord and cortical
layer V at P13 (bottom right in A and C) but not at P4. (B, D) Quantification of fluorescence intensity (expressed in arbitrary units,
AU) revealed a significantly increased glial activation in both ventral (VH) and dorsal horns (DH) of the spinal cord (B) and in cortical
layer V but not layers II-III (D) of SMA mice at P13 (***p<0.001, t-test). Values are expressed as mean ± SEM. Scale bar: 100 µm.
doi: 10.1371/journal.pone.0082654.g007
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proposed as the key step to understand motor neuron loss and
hence pathogenesis in human SMA [47].
All together, these data emphasize the complexity of SMA
pathogenesis, which is likely related to multiple factors
converging in affecting the integrity and function of the
neuromuscular unit. Our data suggest that larger motor
neurons and specific motor neuron pools (for axial and
proximal forelimb muscles) in the cervical spinal cord are more
vulnerable, either for selective loss or specific developmental
impairment leading to motor neurons of smaller size. Motor
neurons for axial and proximal muscles supply a large number
of terminal motor units in a complex tridimensional fashion.
Since SMN is likely involved in axonal transport of relevant
molecules [12,48], this function might be more easily
challenged in motor neurons with extensive axonal branching
that support many different terminal motor units.
Cortical changes
Even though it is generally reported in literature that SMA
patients “only showed decreased numbers of anterior horn
cells in the spinal cord, with no change in the cortical pyramidal
cells, including the Betz cells, and no degeneration of the
pyramidal tracts” [49], we have surprisingly detected a selective
decrease in the number of large layer V pyramidal neurons in
the motor cortex, indicating that also upper motor neurons
degenerate/undergo atrophy in ∆7 SMA murine brain. By
contrast, layer II-III neurons in the motor cortex did not show
cell loss. The decrease in the density of large size layer V
pyramids can be related to the loss of target lower motor
neurons. It might be due to cell shrinkage, in absence of
neuronal death, as described after corticospinal tract section
[50], possibly for the lack of trophic support [51]. Even if the
death of cortical motor neurons following lower motor neurons
loss is unlikely, since only damage close to cortical neuron
soma can cause cell death [52], it cannot be entirely ruled out
since immature corticospinal neurons are strictly dependent on
their target [53]. Indeed, cortical neuronal death was reported
during prenatal brain development in severe SMA mice [54].
Clear abnormalities of brain morphology and development
were reported post-natally in the same mouse model, in both
neocortex and hippocampus [55]. Together with the latter data
on hippocampus and the reduced sensory input to spinal motor
neurons [39], our results emphasize that SMN deficiency
deeply alters the development and fate of multiple neuronal
subpopulations.
Astrogliosis
Finally, we observed a marked gliosis both in the spinal cord
and in the cerebral cortex of affected mice at P13, whose
location matched that of motor neuron and layer V pyramidal
cell loss. The astrocytic network plays an important role in
synaptic function and plasticity by providing metabolic support
to neurons and participating to the reuptake and release of
neuro-transmitters [56,57] and it might be relevant in the
pathogenesis of neurodegenerative diseases. Activated
astrocytes can either assure a permissive substrate for axonal
regeneration/sprouting and produce neurotrophins and anti-
inflammatory cytokines, or favor motor neuron degeneration
and death by releasing toxic molecules, inducing oxidative
stress, and upregulating pro-inflammatory cytokines [58]. In this
respect, intramuscular administration of adenoviral vectors
expressing cardiotrophin-1 improved motor performance and
increased survival in a SMA model [59], indicating that
cytokines might modulate the neurodegenerative process in
SMA. The present data are in agreement with the report of
gliosis in the spinal cord of SMAI and SMAII patients [47], and
support the idea that also neuroinflammation should be
considered as a potential therapeutic target for tackling SMA.
Conclusion
In summary, we show here the detrimental effect of reduced
levels of SMN protein in lower and upper motor neurons and
the time-course of their loss, and the selective involvement of
motor neuron pools, extending our current knowledge on SMA
neuropathological hallmarks. The pathogenesis of SMA is likely
more complex than previously anticipated, involving neuronal
and non-neuronal systems, as demonstrated by the report of
cardiac muscle defects and glucose intolerance in SMA
patients and mouse models [15,60,61]. Our findings should
stimulate further analyses of the neuropathology and clinics of
SMA. Different promising therapeutic approaches for SMA are
now developing, and our study suggests that their target should
not be directed to lower motor neurons only. Understanding
properly the nature and progression of the
anatomopathological manifestations of the disease can give
useful suggestions on the timing of therapeutic interventions to
prevent their occurrence.
Supporting Information
Figure S1.  Soma size distribution of phrenic nucleus and
motor pool innervating distal muscles. Analysis of soma
size distribution of phrenic MNs (A) and in MNs innervating
distal muscles (B) did not reveal evident changes in SMA
compared to WT mice both at P4 (left) and P13 (right) stages.
(TIF)
Figure S2.  Soma size analysis of cortical motor neurons in
WT and SMA mice. (A) Mean cross-sectional areas of cortical
neurons in layers V and II-III at P9 revealed a slight, non-
significant size reduction in SMA vs WT mice (layer V: 47.5 ±
5.2 µm2 in SMA vs 54.2 ± 5 µm2 in WT; layers II-III: 40 ± 2.7
µm2 in SMA vs 51.6 ± 9 µm2 in WT, p>0.05, t-test). (B-C) Area
distribution analysis (20 µm2 bins) did not reveal significant
changes between WT and SMA mice at P9 in both layers V (B)




The authors wish to thank Dr. Francesca Colciaghi, Adele
Finardi and Paola Nobili for discussing scientific data and the
artwork and Dr. Maddalena Fratelli for the statistical analysis.
Motoneuronal Vulnerability in Delta7 SMA Mice
PLOS ONE | www.plosone.org 12 December 2013 | Volume 8 | Issue 12 | e82654
Author Contributions
Conceived and designed the experiments: AV GSB PD MB.
Performed the experiments: PD MB AP VV EDA. Analyzed the
data: PD MB DL. Contributed reagents/materials/analysis tools:
SC FV. Wrote the manuscript: PD MB AV GSB.
References
1. Prior TW, Snyder PJ, Rink BD, Pearl DK, Pyatt RE et al. (2010)
Newborn and carrier screening for spinal muscular atrophy. Am J Med
Genet A 152A: 1608-1616. doi:10.1002/ajmg.a.33474. PubMed:
20578137.
2. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P et al. (1995)
Identification and characterization of a spinal muscular atrophy-
determining gene. Cell 80: 155-165. doi:
10.1016/0092-8674(95)90460-3. PubMed: 7813012.
3. Gennarelli M, Lucarelli M, Capon F, Pizzuti A, Merlini L et al. (1995)
Survival motor neuron gene transcript analysis in muscles from spinal
muscular atrophy patients. Biochem Biophys Res Commun 213:
342-348. doi:10.1006/bbrc.1995.2135. PubMed: 7639755.
4. Lorson CL, Hahnen E, Androphy EJ, Wirth B (1999) A single nucleotide
in the SMN gene regulates splicing and is responsible for spinal
muscular atrophy. Proc Natl Acad Sci U S A 96: 6307-6311. doi:
10.1073/pnas.96.11.6307. PubMed: 10339583.
5. Monani UR, McPherson JD, Burghes AH (1999) Promoter analysis of
the human centromeric and telomeric survival motor neuron genes
(SMNC and SMNT). Biochim Biophys Acta 1445: 330-336. doi:10.1016/
S0167-4781(99)00060-3. PubMed: 10366716.
6. Vitali T, Sossi V, Tiziano F, Zappata S, Giuli A et al. (1999) Detection of
the survival motor neuron (SMN) genes by FISH: further evidence for a
role for SMN2 in the modulation of disease severity in SMA patients.
Hum Mol Genet 8: 2525-2532. doi:10.1093/hmg/8.13.2525. PubMed:
10556301.
7. Wirth B, Brichta L, Hahnen E (2006) Spinal muscular atrophy: from
gene to therapy. Semin Pediatr Neurol 13: 121-131. doi:10.1016/j.spen.
2006.06.008. PubMed: 17027862.
8. Pellizzoni L, Kataoka N, Charroux B, Dreyfuss G (1998) A novel
function for SMN, the spinal muscular atrophy disease gene product, in
pre-mRNA splicing. Cell 95: 615-624. doi:10.1016/
S0092-8674(00)81632-3. PubMed: 9845364.
9. Zhang Z, Lotti F, Dittmar K, Younis I, Wan L et al. (2008) SMN
deficiency causes tissue-specific perturbations in the repertoire of
snRNAs and widespread defects in splicing. Cell 133: 585-600. doi:
10.1016/j.cell.2008.03.031. PubMed: 18485868.
10. Battaglia G, Princivalle A, Forti F, Lizier C, Zeviani M (1997) Expression
of the SMN gene, the spinal muscular atrophy determining gene, in the
mammalian central nervous system. Hum Mol Genet 6: 1961-1971. doi:
10.1093/hmg/6.11.1961. PubMed: 9302277.
11. Pagliardini S, Giavazzi A, Setola V, Lizier C, Di Luca M et al. (2000)
Subcellular localization and axonal transport of the survival motor
neuron (SMN) protein in the developing rat spinal cord. Hum Mol Genet
9: 47-56. doi:10.1093/hmg/9.1.47. PubMed: 10587577.
12. Rossoll W, Jablonka S, Andreassi C, Kröning AK, Karle K et al. (2003)
Smn, the spinal muscular atrophy-determining gene product, modulates
axon growth and localization of beta-actin mRNA in growth cones of
motoneurons. J Cell Biol 163: 801-812. doi:10.1083/jcb.200304128.
PubMed: 14623865.
13. Shafey D, MacKenzie AE, Kothary R (2008) Neurodevelopmental
abnormalities in neurosphere-derived neural stem cells from SMN-
depleted mice. J Neurosci Res 86: 2839-2847. doi:10.1002/jnr.21743.
PubMed: 18521935.
14. Setola V, Terao M, Locatelli D, Bassanini S, Garattini E et al. (2007)
Axonal-SMN (a-SMN), a protein isoform of the survival motor neuron
gene, is specifically involved in axonogenesis. Proc Natl Acad Sci U S
A 104: 1959-1964. doi:10.1073/pnas.0610660104. PubMed: 17261814.
15. Bowerman M, Swoboda KJ, Michalski JP, Wang GS, Reeks C et al.
(2012) Glucose metabolism and pancreatic defects in spinal muscular
atrophy. Ann Neurol 72: 256-268. doi:10.1002/ana.23582. PubMed:
22926856.
16. Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM et al. (2000) A
mouse model for spinal muscular atrophy. Nat Genet 24: 66-70. doi:
10.1038/71709. PubMed: 10615130.
17. Le TT, Pham LT, Butchbach ME, Zhang HL, Monani UR et al. (2005)
SMNDelta7, the major product of the centromeric survival motor neuron
(SMN2) gene, extends survival in mice with spinal muscular atrophy
and associates with full-length SMN. Hum Mol Genet 14: 845-857. doi:
10.1093/hmg/ddi078. PubMed: 15703193.
18. Monani UR, Sendtner M, Coovert DD, Parsons DW, Andreassi C et al.
(2000) The human centromeric survival motor neuron gene (SMN2)
rescues embryonic lethality in Smn(-/-) mice and results in a mouse
with spinal muscular atrophy. Hum Mol Genet 9: 333-339. doi:
10.1093/hmg/9.3.333. PubMed: 10655541.
19. Schrank B, Götz R, Gunnersen JM, Ure JM, Toyka KV et al. (1997)
Inactivation of the survival motor neuron gene, a candidate gene for
human spinal muscular atrophy, leads to massive cell death in early
mouse embryos. Proc Natl Acad Sci U S A 94: 9920-9925. doi:10.1073/
pnas.94.18.9920. PubMed: 9275227.
20. Monani UR, Pastore MT, Gavrilina TO, Jablonka S, Le TT et al. (2003)
A transgene carrying an A2G missense mutation in the SMN gene
modulates phenotypic severity in mice with severe (type I) spinal
muscular atrophy. J Cell Biol 160: 41-52. doi:10.1083/jcb.200208079.
PubMed: 12515823.
21. Workman E, Saieva L, Carrel TL, Crawford TO, Liu D et al. (2009) A
SMN missense mutation complements SMN2 restoring snRNPs and
rescuing SMA mice. Hum Mol Genet 18: 2215-2229. doi:10.1093/hmg/
ddp157. PubMed: 19329542.
22. Jablonka S, Schrank B, Kralewski M, Rossoll W, Sendtner M (2000)
Reduced survival motor neuron (Smn) gene dose in mice leads to
motor neuron degeneration: an animal model for spinal muscular
atrophy type III. Hum Mol Genet 9: 341-346. doi:10.1093/hmg/9.3.341.
PubMed: 10655542.
23. DiDonato CJ, Lorson CL, De Repentigny Y, Simard L, Chartrand C et
al. (2001) Regulation of murine survival motor neuron (Smn) protein
levels by modifying Smn exon 7 splicing. Hum Mol Genet 10:
2727-2736. doi:10.1093/hmg/10.23.2727. PubMed: 11726560.
24. Foust KD, Wang X, McGovern VL, Braun L, Bevan AK et al. (2010)
Rescue of the spinal muscular atrophy phenotype in a mouse model by
early postnatal delivery of SMN. Nat Biotechnol 28: 271-274. doi:
10.1038/nbt.1610. PubMed: 20190738.
25. Hua Y, Sahashi K, Rigo F, Hung G, Horev G et al. (2011) Peripheral
SMN restoration is essential for long-term rescue of a severe spinal
muscular atrophy mouse model. Nature 478: 123-126. doi:10.1038/
nature10485. PubMed: 21979052.
26. Passini MA, Bu J, Roskelley EM, Richards AM, Sardi SP et al. (2010)
CNS-targeted gene therapy improves survival and motor function in a
mouse model of spinal muscular atrophy. J Clin Invest 120: 1253-1264.
doi:10.1172/JCI41615. PubMed: 20234094.
27. Kariya S, Park GH, Maeno-Hikichi Y, Leykekhman O, Lutz C et al.
(2008) Reduced SMN protein impairs maturation of the neuromuscular
junctions in mouse models of spinal muscular atrophy. Hum Mol Genet
17: 2552-2569. doi:10.1093/hmg/ddn156. PubMed: 18492800.
28. Vercelli A, Mereuta OM, Garbossa D, Muraca G, Mareschi K et al.
(2008) Human mesenchymal stem cell transplantation extends survival,
improves motor performance and decreases neuroinflammation in
mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 31:
395-405. doi:10.1016/j.nbd.2008.05.016. PubMed: 18586098.
29. West MJ, Slomianka L, Gundersen HJ (1991) Unbiased stereological
estimation of the total number of neurons in the subdivisions of the rat
hippocampus using the optical fractionator. Anat Rec 231: 482-497.
doi:10.1002/ar.1092310411. PubMed: 1793176.
30. Watson C, Paxinos G, Kayalioglu G (2009) The spinal cord. Academic
Press. 387pp.
31. Franklin KBJ, Paxinos G (2008) The mouse brain in stereotaxic
coordinates, 3rd edition. Academic Press.
32. Soler-Botija C, Ferrer I, Gich I, Baiget M, Tizzano EF (2002) Neuronal
death is enhanced and begins during foetal development in type I
spinal muscular atrophy spinal cord. Brain 125: 1624-1634. doi:
10.1093/brain/awf155. PubMed: 12077011.
33. Avila AM, Burnett BG, Taye AA, Gabanella F, Knight MA et al. (2007)
Trichostatin A increases SMN expression and survival in a mouse
model of spinal muscular atrophy. J Clin Invest 117: 659-671. doi:
10.1172/JCI29562. PubMed: 17318264.
34. Ling KK, Gibbs RM, Feng Z, Ko CP (2012) Severe neuromuscular
denervation of clinically relevant muscles in a mouse model of spinal
muscular atrophy. Hum Mol Genet 21: 185-195. doi:10.1093/hmg/
ddr453. PubMed: 21968514.
Motoneuronal Vulnerability in Delta7 SMA Mice
PLOS ONE | www.plosone.org 13 December 2013 | Volume 8 | Issue 12 | e82654
35. Kong L, Wang X, Choe DW, Polley M, Burnett BG et al. (2009)
Impaired synaptic vesicle release and immaturity of neuromuscular
junctions in spinal muscular atrophy mice. J Neurosci 29: 842-851. doi:
10.1523/JNEUROSCI.4434-08.2009. PubMed: 19158308.
36. Murray LM, Comley LH, Thomson D, Parkinson N, Talbot K et al.
(2008) Selective vulnerability of motor neurons and dissociation of pre-
and post-synaptic pathology at the neuromuscular junction in mouse
models of spinal muscular atrophy. Hum Mol Genet 17: 949-962.
PubMed: 18065780.
37. Ruiz R, Casañas JJ, Torres-Benito L, Cano R, Tabares L (2010)
Altered intracellular Ca2+ homeostasis in nerve terminals of severe
spinal muscular atrophy mice. J Neurosci 30: 849-857. doi:10.1523/
JNEUROSCI.4496-09.2010. PubMed: 20089893.
38. Ling KK, Lin MY, Zingg B, Feng Z, Ko CP (2010) Synaptic defects in
the spinal and neuromuscular circuitry in a mouse model of spinal
muscular atrophy. PLOS ONE 5: e15457. doi:10.1371/journal.pone.
0015457. PubMed: 21085654.
39. Mentis GZ, Blivis D, Liu W, Drobac E, Crowder ME et al. (2011) Early
functional impairment of sensory-motor connectivity in a mouse model
of spinal muscular atrophy. Neuron 69: 453-467. doi:10.1016/j.neuron.
2010.12.032. PubMed: 21315257.
40. McGovern VL, Gavrilina TO, Beattie CE, Burghes AH (2008)
Embryonic motor axon development in the severe SMA mouse. Hum
Mol Genet 17: 2900-2909. doi:10.1093/hmg/ddn189. PubMed:
18603534.
41. Pun S, Sigrist M, Santos AF, Ruegg MA, Sanes JR et al. (2002) An
intrinsic distinction in neuromuscular junction assembly and
maintenance in different skeletal muscles. Neuron 34: 357-370. doi:
10.1016/S0896-6273(02)00670-0. PubMed: 11988168.
42. Lee YI, Mikesh M, Smith I, Rimer M, Thompson W (2011) Muscles in a
mouse model of spinal muscular atrophy show profound defects in
neuromuscular development even in the absence of failure in
neuromuscular transmission or loss of motor neurons. Dev Biol 356:
432-444. doi:10.1016/j.ydbio.2011.05.667. PubMed: 21658376.
43. Simic G, Seso-Simic D, Lucassen PJ, Islam A, Krsnik Z et al. (2000)
Ultrastructural analysis and TUNEL demonstrate motor neuron
apoptosis in Werdnig-Hoffmann disease. J Neuropathol Exp Neurol 59:
398-407. PubMed: 10888370.
44. Soler-Botija C, Ferrer I, Alvarez JL, Baiget M, Tizzano EF (2003)
Downregulation of Bcl-2 proteins in type I spinal muscular atrophy
motor neurons during fetal development. J Neuropathol Exp Neurol 62:
420-426. PubMed: 12722834.
45. Sisó S, Pumarola M, Ferrer I (2003) Cell death and decreased synaptic
protein expression in the ventral horn of Holstein-Friesian calves with
spinal muscular atrophy. J Comp Pathol 128: 132-139. doi:10.1053/
jcpa.2002.0616. PubMed: 12634090.
46. Tsai LK, Tsai MS, Ting CH, Wang SH, Li H (2008) Restoring Bcl-x(L)
levels benefits a mouse model of spinal muscular atrophy. Neurobiol
Dis 31: 361-367. doi:10.1016/j.nbd.2008.05.014. PubMed: 18590823.
47. Simic G, Mladinov M, Seso Simic D, Jovanov Milosevic N, Islam A et
al. (2008) Abnormal motoneuron migration, differentiation, and axon
outgrowth in spinal muscular atrophy. Acta Neuropathol 115: 313-326.
doi:10.1007/s00401-007-0327-1. PubMed: 18075747.
48. Zhang H, Xing L, Rossoll W, Wichterle H, Singer RH et al. (2006)
Multiprotein complexes of the survival of motor neuron protein SMN
with Gemins traffic to neuronal processes and growth cones of motor
neurons. J Neurosci 26: 8622-8632. doi:10.1523/JNEUROSCI.
3967-05.2006. PubMed: 16914688.
49. Huang K, Luo Y (1983) Adult spinal muscular atrophy. A report of four
cases. J Neurol Sci 61: 249-259. doi:10.1016/0022-510X(83)90009-6.
PubMed: 6644327.
50. Wannier T, Schmidlin E, Bloch J, Rouiller EM (2005) A unilateral
section of the corticospinal tract at cervical level in primate does not
lead to measurable cell loss in motor cortex. J Neurotrauma 22:
703-717. doi:10.1089/neu.2005.22.703. PubMed: 15941378.
51. Kobayashi NR, Fan DP, Giehl KM, Bedard AM, Wiegand SJ et al.
(1997) BDNF and NT-4/5 prevent atrophy of rat rubrospinal neurons
after cervical axotomy, stimulate GAP-43 and Talpha1-tubulin mRNA
expression, and promote axonal regeneration. J Neurosci 17:
9583-9595. PubMed: 9391013.
52. Fernandes KJ, Fan DP, Tsui BJ, Cassar SL, Tetzlaff W (1999)
Influence of the axotomy to cell body distance in rat rubrospinal and
spinal motoneurons: differential regulation of GAP-43, tubulins, and
neurofilament-M. J Comp Neurol 414: 495-510. doi:10.1002/
(SICI)1096-9861(19991129)414:4. PubMed: 10531542.
53. Martin JH (2005) The corticospinal system: from development to motor
control. Neuroscientist 11: 161-173. doi:10.1177/1073858404270843.
PubMed: 15746384.
54. Liu H, Shafey D, Moores JN, Kothary R (2010) Neurodevelopmental
consequences of Smn depletion in a mouse model of spinal muscular
atrophy. J Neurosci Res 88: 111-122. doi:10.1002/jnr.22189. PubMed:
19642194.
55. Wishart TM, Huang JP, Murray LM, Lamont DJ, Mutsaers CA et al.
(2010) SMN deficiency disrupts brain development in a mouse model of
severe spinal muscular atrophy. Hum Mol Genet 19: 4216-4228. doi:
10.1093/hmg/ddq340. PubMed: 20705736.
56. Henneberger C, Papouin T, Oliet SH, Rusakov DA (2010) Long-term
potentiation depends on release of D-serine from astrocytes. Nature
463: 232-236. doi:10.1038/nature08673. PubMed: 20075918.
57. Rouach N, Koulakoff A, Abudara V, Willecke K, Giaume C (2008)
Astroglial metabolic networks sustain hippocampal synaptic
transmission. Science 322: 1551-1555. doi:10.1126/science.1164022.
PubMed: 19056987.
58. Papadimitriou D, Le Verche V, Jacquier A, Ikiz B, Przedborski S et al.
(2010) Inflammation in ALS and SMA: sorting out the good from the
evil. Neurobiol Dis 37: 493-502. doi:10.1016/j.nbd.2009.10.005.
PubMed: 19833209.
59. Lesbordes JC, Cifuentes-Diaz C, Miroglio A, Joshi V, Bordet T et al.
(2003) Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse
model of spinal muscular atrophy. Hum Mol Genet 12: 1233-1239. doi:
10.1093/hmg/ddg143. PubMed: 12761038.
60. Bevan AK, Hutchinson KR, Foust KD, Braun L, McGovern VL et al.
(2010) Early heart failure in the SMNDelta7 model of spinal muscular
atrophy and correction by postnatal scAAV9-SMN delivery. Hum Mol
Genet 19: 3895-3905. doi:10.1093/hmg/ddq300. PubMed: 20639395.
61. Rudnik-Schöneborn S, Heller R, Berg C, Betzler C, Grimm T et al.
(2008) Congenital heart disease is a feature of severe infantile spinal
muscular atrophy. J Med Genet 45: 635-638. doi:10.1136/jmg.
2008.057950. PubMed: 18662980.
Motoneuronal Vulnerability in Delta7 SMA Mice
PLOS ONE | www.plosone.org 14 December 2013 | Volume 8 | Issue 12 | e82654
